[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581290":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":29,"responsibleParty":44,"collaborators":48,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":20,"enrollmentInfo":60,"targetDuration":20,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":32,"whyStopped":20,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Region Västmanland","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment with cloxacillin as continuous infusion via elastomeric pump","EXPERIMENTAL","Additional monitoring procedures performed: blood samples drawn before, after 4h, after 24h, and after 48h of continuous infusion of cloxacillin.",[13],"Diagnostic Test: Unbound cloxacillin concentration",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Unbound cloxacillin concentration","Unbound cloxacillin concentration measured at baseline, after 4h, after 24h and after 48h of continuous infusion.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Emeli Månsson, PhD","CONTACT","004621173000","emeli.mansson@regionvastmanland.se",{"name":28,"role":24,"phone":25,"phoneExt":20,"email":20},"Karl-Johan Lindner, PhD",[30],{"facility":31,"status":32,"city":33,"state":20,"zip":20,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Västmanlands sjukhus Västerås","RECRUITING","Västerås","Sweden","SE",{"type":37,"coordinates":38},"Point",[39,40],16.55276,59.61617,{"lat":40,"lon":39},[43],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"SPONSOR_INVESTIGATOR","Emeli Månsson","Principal Investigator",[49],{"name":5,"class":6},"100581290","phase-4-unbound-cloxacillin-concentrations-during-continuous-infusion-100581290",false,"NCT06848387","Unbound Cloxacillin Concentrations During Continuous Infusion","Concentration of Unbound Cloxacillin in Adults Treated With Continuous Infusion Via Elastomeric Pump","KLONC","Inclusion Criteria:\n\n* Age 18 years or older\n* Treating physician has decided to start continuous infusion of cloxacillin\n\nExclusion Criteria:\n\n* Unwilling or unable to provide written informed consent","ALL","18 Years",{"count":61,"type":62},25,"ESTIMATED","INTERVENTIONAL",[65],"PHASE4","Cloxacillin is the first-line choice for the treatment of severe infections caused by the bacterium Staphylococcus aureus in Sweden. Over the past year, cloxacillin is increasingly administred through continuous infusion. In this study, the free (unbound) concentration of cloxacillin when administered as a continuous infusion will be measured to ensure that the free concentration is neither too high nor too low. A PK\u002FPD model will be developed to predict which dosage of cloxacillin is appropriate for an individual based on age, gender, kidney function, and serum-protein level.",[68],"Staphylococcal Infections",[70],"cloxacillin","2026-02-12",{"date":73,"type":74},"2026-02-17","ACTUAL",{"date":76,"type":74},"2026-01-14",{"date":78,"type":62},"2027-12",{"name":46,"class":6},1]